Pioneer Trust Bank N A OR Boosts Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Pioneer Trust Bank N A OR grew its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 25.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 8,580 shares of the company's stock after acquiring an additional 1,760 shares during the period. Pioneer Trust Bank N A OR's holdings in Eli Lilly and Company were worth $5,001,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in LLY. Simon Quick Advisors LLC lifted its position in shares of Eli Lilly and Company by 10.5% during the 4th quarter. Simon Quick Advisors LLC now owns 2,927 shares of the company's stock worth $1,706,000 after buying an additional 278 shares in the last quarter. Clear Harbor Asset Management LLC bought a new position in shares of Eli Lilly and Company during the 4th quarter worth approximately $363,000. Terril Brothers Inc. lifted its position in shares of Eli Lilly and Company by 113.2% during the 4th quarter. Terril Brothers Inc. now owns 808 shares of the company's stock worth $471,000 after buying an additional 429 shares in the last quarter. Hartline Investment Corp lifted its position in shares of Eli Lilly and Company by 1.1% during the 4th quarter. Hartline Investment Corp now owns 21,934 shares of the company's stock worth $12,786,000 after buying an additional 248 shares in the last quarter. Finally, Commonwealth Equity Services LLC lifted its position in shares of Eli Lilly and Company by 5.2% during the 4th quarter. Commonwealth Equity Services LLC now owns 354,565 shares of the company's stock worth $206,683,000 after buying an additional 17,461 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have commented on LLY shares. Truist Financial lifted their target price on shares of Eli Lilly and Company from $850.00 to $892.00 and gave the stock a "buy" rating in a research report on Wednesday, May 1st. The Goldman Sachs Group lifted their price target on shares of Eli Lilly and Company from $650.00 to $723.00 and gave the stock a "neutral" rating in a report on Thursday, April 11th. Morgan Stanley lifted their price target on shares of Eli Lilly and Company from $805.00 to $950.00 and gave the stock an "overweight" rating in a report on Friday, February 16th. Barclays lifted their price objective on shares of Eli Lilly and Company from $680.00 to $810.00 and gave the company an "overweight" rating in a research note on Wednesday, February 7th. Finally, JPMorgan Chase & Co. boosted their price target on shares of Eli Lilly and Company from $850.00 to $900.00 and gave the company an "overweight" rating in a research report on Wednesday, May 1st. Three analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $757.95.

Eli Lilly and Company Trading Down 0.4 %

Eli Lilly and Company stock traded down $3.45 during mid-day trading on Thursday, hitting $771.55. The company's stock had a trading volume of 2,169,264 shares, compared to its average volume of 3,068,803. The company has a debt-to-equity ratio of 1.90, a current ratio of 1.35 and a quick ratio of 1.03. The stock has a market cap of $733.28 billion, a price-to-earnings ratio of 113.63, a price-to-earnings-growth ratio of 1.45 and a beta of 0.37. The business has a 50 day moving average price of $761.56 and a 200-day moving average price of $675.58. Eli Lilly and Company has a 12 month low of $419.80 and a 12 month high of $800.78.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings data on Monday, May 6th. The company reported $2.58 EPS for the quarter, beating the consensus estimate of $2.53 by $0.05. The firm had revenue of $8.77 billion during the quarter, compared to the consensus estimate of $8.94 billion. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. The company's quarterly revenue was up 26.0% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.62 earnings per share. As a group, analysts forecast that Eli Lilly and Company will post 13.82 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, June 10th. Stockholders of record on Thursday, May 16th will be paid a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a dividend yield of 0.67%. The ex-dividend date is Wednesday, May 15th. Eli Lilly and Company's dividend payout ratio (DPR) is 76.58%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.